NIH × Interventional × Sunitinib × Clear all
NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 2 FDA
NCT00387426 2014-05-28

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

National Cancer Institute (NCI)

Phase 2 Terminated
14 enrolled 5 charts
NCT00890747 2014-03-17

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled